ict01,pembrolizumab
merck,imcheck therapeutics
['melanoma', 'nsclc', 'sclc', 'bladder', 'ict01', 'pembro']
 immuno-oncologist superstar presenting preliminary results of ict01, an anti-btn3a that selectively target g9d2 t cells, and pembrolizumab in cpi-pretreated melanoma, nsclc and bladder cancer. encouraging data! 
M.D. - @BERGONIE33 / Ph.D. student - @ExpliCyte @ImmuSmol - @univbordeaux / Immune & Molecular-Target Believer / ???? / Tweets my Own